Drug intelligence / Profile preview

DNTmAb

Development stage: Preclinical
Lead developer: Denteric
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

DNTmAb is a monoclonal antibody currently in preclinical development by Denteric for the treatment of periodontal disease. It is designed to target and neutralize specific virulence factors produced by *Porphyromonas gingivalis*, a keystone pathogen responsible for the inflammation and tissue destruction associated with chronic periodontitis. By binding to these virulence factors, the antibody aims to reduce the bacterial pathogenicity and mitigate the host inflammatory response, potentially providing a targeted therapeutic approach to managing gum disease.

Beyond the preview

Go deeper on DNTmAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNTmAb.

Explore the full profile